Table 3 Estimates of effects and quality ratings for comparison of drugs
Comparison | Direct evidence | Indirect evidence | Network meta-analysis | |||
|---|---|---|---|---|---|---|
RR [95% CI] | Quality of evidence | RR [95% CI] | Quality of evidence | RR [95% CI] | Quality of evidence | |
Incidence of new-onset AF | ||||||
SGLT2i vs Placebo | 0.85 (0.50,1.47) | Low*■ | Not estimable▲ | – | 0.84 (0.48,1.46) | Low*■ |
Finerenone vs Placebo | 0.79 (0.62,0.99) | Moderate■ | Not estimable▲ | – | 0.79 (0.62,0.99) | Moderate■ |
SGLT2i vs Finerenone | – | – | 1.06 (0.58,1.94) | Very Low ● | 1.06 (0.58,1.94) | Very Low ● |
Major adverse cardiovascular events | ||||||
SGLT2i vs Placebo | 0.81 (0.74,0.89) | High | Not estimable▲ | – | 0.81 (0.75,0.89) | High |
Finerenone vs Placebo | 0.88 (0.80,0.97) | High | Not estimable▲ | – | 0.88 (0.80,0.97) | High |
SGLT2i vs Finerenone | – | – | 0.93 (0.81,1.06) | Moderate● | 0.93 (0.81,1.06) | Moderate● |
Hospitalization for heart failure | ||||||
SGLT2i vs Placebo | 0.62 (0.53,0.72) | Moderate■ | Not estimable▲ | – | 0.62 (0.53,0.72) | Moderate■ |
Finerenone vs Placebo | 0.79 (0.67,0.92) | Moderate■ | Not estimable▲ | – | 0.79 (0.67,0.92) | Moderate■ |
SGLT2i vs Finerenone | – | – | 0.78 (0.63,0.98) | Low● | 0.78 (0.63,0.98) | Low● |
Nonfatal stroke | ||||||
SGLT2i vs Placebo | 0.77 (0.62,0.97) | Moderate■ | Not estimable▲ | – | 0.78 (0.62,0.97) | Moderate■ |
Finerenone vs Placebo | 1.00 (0.82,1.21) | Moderate■ | Not estimable▲ | – | 1.00 (0.82,1.21) | Moderate■ |
SGLT2i vs Finerenone | – | – | 0.78 (0.58,1.05) | Low● | 0.78 (0.58,1.05) | Low● |
Adverse events | ||||||
SGLT2i vs Placebo | 0.98 (0.96,1.00) | Low*▷ | Not estimable▲ | – | 0.98 (0.96,1.00) | Low*▷ |
Finerenone vs Placebo | 1.00 (0.99,1.01) | Moderate▷ | Not estimable▲ | – | 1.00 (0.98,1.01) | Moderate▷ |
SGLT2i vs Finerenone | – | – | 0.99 (0.96,1.01) | Very Low● | 0.98 (0.96,1.00) | Very Low● |
Serious adverse events | ||||||
SGLT2i vs Placebo | 0.89 (0.81,0.99) | Moderate* | Not estimable▲ | – | 0.90 (0.86,0.93) | Moderate* |
Finerenone vs Placebo | 0.94 (0.90,0.99) | High | Not estimable▲ | – | 0.94 (0.90,0.99) | High |
SGLT2i vs Finerenone | – | – | 0.95 (0.89,1.02) | Low● | 0.95 (0.89,1.02) | Low● |
Serious hyperkalemia | ||||||
SGLT2i vs Placebo | 1.00 (0.42,2.39) | Moderate■ | Not estimable▲ | – | 1.00 (0.42,2.39) | Moderate■ |
Finerenone vs Placebo | 4.16 (2.45,7.08) | Moderate■ | Not estimable▲ | – | 4.08 (2.39,6.96) | Moderate■ |
SGLT2i vs Finerenone | – | – | 0.25 (0.09,0.68) | Low● | 0.25 (0.09,0.68) | Low● |